Search Results - "Branella, Gianna M"

Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing by Branella, Gianna M, Spencer, Harold Trent

“…Chimeric antigen receptor (CAR) T-cell therapy has been widely successful in the treatment of B-cell malignancies, including B-cell lymphoma, mantle cell…”
Get full text

Directing the migration of serum-free, ex vivo -expanded Vγ9Vδ2 T cells by Parwani, Kiran K, Branella, Gianna M, Burnham, Rebecca E, Burnham, Andre J, Bustamante, Austre Y Schiaffino, Foppiani, Elisabetta Manuela, Knight, Kristopher A, Petrich, Brian G, Horwitz, Edwin M, Doering, Christopher B, Spencer, H Trent

“…Vγ9Vδ2 T cells represent a promising cancer therapy platform because the implementation of allogenic, off-the-shelf product candidates is possible. However,…”
Get full text

Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia by Branella, Gianna M, Lee, Jasmine Y, Okalova, Jennifer, Parwani, Kiran K, Alexander, Jordan S, Arthuzo, Raquel F, Fedanov, Andrew, Yu, Bing, McCarty, David, Brown, Harrison C, Chandrakasan, Shanmuganathan, Petrich, Brian G, Doering, Christopher B, Spencer, H Trent

“…The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid…”
Get full text

Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction by Coyle, Christopher W., Knight, Kristopher A., Brown, Harrison C., George, Stephan N., Denning, Gabriela, Branella, Gianna M., Childers, Kenneth C., Spiegel, P. Clint, Spencer, H. Trent, Doering, Christopher B.

“…Laboratory resurrection of ancient coagulation factor (F) IX variants generated through ancestral sequence reconstruction led to the discovery of a…”
Get full text

MERTK inhibition selectively activates a DC - T-cell axis to provide anti-leukemia immunity by Huelse, Justus M, Bhasin, Swati S, Jacobsen, Kristen M, Yim, Juhye, Thomas, Beena E, Branella, Gianna M, Bakhtiari, Mojtaba, Chimenti, Madison L, Baxter, Travon A, Raikar, Sunil S, Wang, Xiaodong, Frye, Stephen V, Henry, Curtis J, Earp, H Shelton, Bhasin, Manoj, DeRyckere, Deborah, Graham, Douglas K

“…TAM-family tyrosine kinases (TYRO3, AXL and MERTK) are potential cancer therapeutic targets. In previous studies MERTK inhibition in the immune…”
Get full text

Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells by Zoine, Jaquelyn T., Prince, Chengyu, Story, Jamie Y., Branella, Gianna M., Lytle, Allison M., Fedanov, Andrew, Alexander, Jordan S., Porter, Christopher C., Doering, Christopher B., Spencer, H. Trent, Chandrakasan, Shanmuganathan

“…While targeting CD19+ hematologic malignancies with CAR T cell therapy using single chain variable fragments (scFv) has been highly successful, novel…”
Get full text

Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma by Lee, Jasmine Y., Jonus, Hunter C., Sadanand, Arhanti, Branella, Gianna M., Maximov, Victor, Suttapitugsakul, Suttipong, Schniederjan, Matthew J., Shim, Jenny, Ho, Andrew, Parwani, Kiran K., Fedanov, Andrew, Pilgrim, Adeiye A., Silva, Jordan A., Schnepp, Robert W., Doering, Christopher B., Wu, Ronghu, Spencer, H. Trent, Goldsmith, Kelly C.

“…GD2-targeting immunotherapies have improved survival in children with neuroblastoma, yet on-target, off-tumor toxicities can occur and a subset of patients…”
Get full text